Plea for TB drug generic production in India The use of bedaquiline and delamanid has been recommended but, the petitioners have said, the limited supplies make them unavailable to patients
Bombay High Court on Wednesday directed the Centre to respond to a petition seeking legal steps to allow generic production of two patented anti-tuberculosis drugs currently unavailable to all patients in India who need them.
The court has asked the Centre to respond by April 28 to the petition by two TB survivors seeking a government use authorisation order or compulsory licence provisions in Indian patent laws to allow local production of the drugs bedaquiline and delamanid.